Genzyme, Biogen Idec Stocks Mixed on Icahn News

Shares of Massachusetts’ two leading biotechs, Genzyme and Biogen Idec, showed a mixed response to last night’s news from SEC filings that activist investor Carl Icahn was showing increased interest in the firms. Biogen, where Icahn almost tripled his previous stake, to 8.8 millon shares, fell $0.09, to $69.92. Genzyme, where Icahn took a new stake of nearly 1 percent, rose $2.08 (nearly 3 percent), to $72.84.

Bob is Xconomy's founder and chairman. You can email him at bbuderi@xconomy.com. Follow @bbuderi

Trending on Xconomy